<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02443727</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001225</org_study_id>
    <nct_id>NCT02443727</nct_id>
  </id_info>
  <brief_title>The Role of Oxytocin in the Perception of Faces</brief_title>
  <official_title>The Role of Oxytocin in the Perception of Infant Faces</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rodrigo Cardenas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. National Science Foundation</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this project is to study whether intranasal oxytocin (OT) affects how
      young adults perceive and attend to infant and adult faces. Based on existing research the
      investigators predict that oxytocin will facilitate the allocation of attentional resources
      on infant faces (compared to adult faces). The investigators also predict that oxytocin will
      enhance the activity of reward neural-networks associated with the perception of infant
      faces. The behavioral effects of OT (visual attention and face recognition) will be measured
      with eye-tracking while participants look at photographs of adult and infant faces.
      Neurological effects (the activity of emotion and reward networks) will be measured with
      functional Magnetic Resonance Imaging (fMRI) while participants look at infant faces on a
      computer screen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Magnetic Resonance Imaging (fMRI) Data</measure>
    <time_frame>45 minutes after OT manipulation</time_frame>
    <description>The effect of OT will be assessed by determining changes in brain activation between treatment and placebo groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eye movements data</measure>
    <time_frame>45 minutes after OT manipulation</time_frame>
    <description>The effect of OT will be assessed by determining changes in eye movements between treatment and placebo groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implicit Attitudes toward infants</measure>
    <time_frame>45 minutes after OT manipulation</time_frame>
    <description>Implicit attitudes toward infants as measured by the Implicit Association Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Theory of mind</measure>
    <time_frame>45 minutes after OT manipulation</time_frame>
    <description>Theory of mind as measured by the Reading the mind in the eyes test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Intranasal oxytocin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will self-administer a single dose of 24 IU oxytocin (Syntocinon, Novartis; three puffs per nostril, each with 4 IU oxytocin, 6 puffs total).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo is identical to the oxytocin formulation with the exception of the active compound.
Participants will self-administer three puffs per nostril of placebo (6 puffs total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syntocinon (synthetic oxytocin)</intervention_name>
    <description>Dosage and details described in arm.</description>
    <arm_group_label>Intranasal oxytocin group</arm_group_label>
    <other_name>OT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage and details described in arm.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Volunteers

          -  Norma or corrected to norma vision

          -  Participants are non parents

          -  Able to provide written informed consent and to comply with all study procedures

        Exclusion Criteria:

          -  Dementia or severe cognitive disorders

          -  Endocrine disease or malignancy

          -  Nasal obstruction or upper-respiratory tract infection

          -  Current or previous psychiatric disorder

          -  Current or previous use of psychoactive drugs

          -  Alcoholism or substance abuse

          -  History of seizures

          -  Neurological Disorder

          -  Previous head trauma

          -  Hypertension

          -  Cardiovascular Disease

          -  Claustrophobia

          -  ferrous metal in any part of the body
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo A Cardenas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>May 27, 2017</last_update_submitted>
  <last_update_submitted_qc>May 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>Rodrigo Cardenas</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

